HPV and condom labeling
This article was originally published in The Gray Sheet
Executive Summary
House Government Reform/Human Resources Subcommittee hearing Jan. 28 on human papillomavirus and the "best strategies" to prevent HPV infection postponed until Feb. 5 (1"The Gray Sheet" Jan.12, 2004, p. 17). The National Cancer Institute had been asked to testify on HPV and cervical cancer vaccine research, diagnostic technologies, treatment options, consequences and prevention strategies by Subcommittee Chair Mark Souder (R-Ind.). Also asked to testify were the heads of CDC, FDA and CMS...
You may also be interested in...
HPV Diagnostics, Condom Labeling Will Be Focus Of Jan. 28 House Hearing
FDA and the National Cancer Institute are among federal agencies asked to testify on cervical cancer prevention and research at a Jan. 28 hearing of the House Government Reform/Human Resources Subcommittee
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.